MeiraGTx stock gained 2.08 percent on October 7 as officer sold shares

Published on 10/08/2026 at 04:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

MeiraGTx stock carries a Moderate Buy consensus from nine analysts, with a USD 24.71 average target on October 2, 2026. Q2 revenue reached USD 321.43 million versus USD 0.70 million expected.

MGTX, KYG596651029, Illustration mit AI erstellt.

MeiraGTx Holdings plc (ISIN KYG596651029) was last at USD 10.82 on Nasdaq on October 7, 2026 at 4:00 p.m. ET, up 2.08 percent. According to Investing.com on October 6, 2026, Chief Scientific Officer Stuart Naylor sold 27,659 ordinary shares for USD 294,291.

Officer sale follows a trading plan

The shares changed hands between USD 10.53 and USD 10.88, with a weighted average price of USD 10.64. The transaction used a Rule 10b5-1 plan adopted on December 9, 2025, and left Naylor with 613,187 ordinary shares, according to MarketBeat.

The transaction is a scheduled-plan sale rather than a discretionary trade described by the filing coverage. That distinction matters because the stock gained 2.08 percent in the October 7 session even as the insider transaction became public.

Quarterly numbers reset the baseline

MeiraGTx reported quarterly EPS of USD 1.71 for the second quarter of 2026, compared with a consensus loss of USD 0.46. Revenue reached USD 321.43 million versus analyst expectations of USD 0.70 million, according to MarketBeat.

The company describes itself as a vertically integrated genetic-medicines developer with late-stage programs in Parkinson's disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy, according to its MeiraGTx investor page.

Analysts see room above USD 10.82

MarketBeat reported on October 2, 2026, that nine analysts assigned MeiraGTx a Moderate Buy consensus and an average 12-month price target of USD 24.71. The target lies 128.4 percent above the USD 10.82 reference price, while the stock remains 29.5 percent below its 52-week high of USD 15.35.

Market value stays near USD 1.0 billion

MGTX had a market capitalization of USD 1.0 billion and trading volume of 2,309,854 shares on October 7, 2026. Its 52-week range was USD 6.62 to USD 15.35, placing the latest quote materially above the low while leaving valuation expectations dependent on clinical and commercial execution.